Germinoma
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
| Germinoma Classification and external resources | |
| ICD-O: | 9060-9061 |
|---|---|
| MeSH | D018237 |
| Dysgerminoma Classification and external resources | |
| ICD-9 | 183.0 |
|---|---|
| ICD-O: | 9060/3 |
| MeSH | D004407 |
| Seminoma Classification and external resources | |
| ICD-10 | C62. |
|---|---|
| ICD-9 | 186 |
| ICD-O: | 9061 |
| OMIM | 273300 |
| DiseasesDB | 12966 |
| eMedicine | med/2250 |
| MeSH | D018239 |
|
WikiDoc Resources for Germinoma | |
|
Articles | |
|---|---|
|
Most recent articles on Germinoma | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Germinoma at Clinical Trials.gov Clinical Trials on Germinoma at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Germinoma
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Germinoma Discussion groups on Germinoma Directions to Hospitals Treating Germinoma Risk calculators and risk factors for Germinoma
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Germinoma | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
A germinoma is a type of germ cell tumor[1] which is not differentiated upon examination.[1] It may be benign or malignant.
Classification
The term germinoma most often has referred to a tumor in the brain that has a histology identical to two other tumors: dysgerminoma in the ovary and seminoma in the testis.[1] Increasingly, the term refers to any tumor with this histology, regardless of where it occurs in the body.
MeSH defines germinoma as "a malignant neoplasm of the germinal tissue of the gonads; mediastinum; or pineal region"[1] and within its scope includes both dysgerminoma and seminoma. Collectively, these are the seminomatous or germinomatous tumors.
Natural history
Malignant transformation of primordial germ cells that inappropriately migrated during development (either failing to migrate into or out of an area) are the originators of germinomas. There is no histologic differentiation whereas nongerminomatous germ cell tumors display a variety of differentiation.
Histology
The tumor is uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular cytoplasm that is eosinophilic.
On gross examination, the external surface is smooth and bosselated (knobby), and the interior is soft, fleshy and either cream-coloured, gray, pink or tan. Microscopic examination typically reveals uniform cells that resemble primordial germ cells. Typically, the stroma contains lymphocytes and about 20% of patients have sarcoid-like granulomas.
Diagnosis
Metastasis has been noted in approximately 22% of cases at time of diagnosis. Males are approximately twice as commonly affected in developing germinomas. Germinomas are most commonly diagnosed between the age of 10 and 21.
Often serum and spinal fluid tumor markers of AFP and beta-HCG are tested. Pure germinomas are not associated with these markers. Nongerminomatous germ cell tumors may be associated with increased markers such as AFP with yolk sac tumors as well as embryonic cell carcinomas and immature teratomas and beta-HCG which occur in choriocarcinomas. It should be noted that in 1-15% of germinonas a low level of beta-HCG may be produced. Although controversial, there are some thoughts that HCG-secreting germinomas are more aggressive than nonsecreting ones.
Locations
Ovary (dysgerminoma)
Dysgerminoma is the most common type of malignant germ cell ovarian cancer. Dysgerminoma usually occurs in adolescence and early adult life; about 5% occur in pre-pubertal children. Dysgerminoma is extremely rare after age 50. Dysgerminoma occurs in both ovaries in 10% of patients and, in a further 10%, there is microscopic tumor in the other ovary.
Abnormal gonads (due to gonadal dysgenesis and androgen insensitivity syndrome) have a high risk of developing a dysgerminoma. Most dysgerminomas are associated with elevated serum lactic dehydrogenase (LDH), which is sometimes used as a tumor marker.
Metastases are most often present in the lymph nodes.
Intracranial germinoma
Intracranial germinoma occurs in 0.7 per million children.[1] As with other germ cell tumors (GCTs) occurring outside the gonads, the most common location of intracranial germinoma is on or near the midline, often in the pineal or suprasellar areas; in 5-10% of patients with germinoma in either area, the tumor is in both areas. Like other (GCTs), germinomas can occur in other areas of the brain. Within the brain, this tumor is most common in the hypothalamic or epiphysial regions. In the thalamus and basal ganglia, germinoma is the most common GCT.
The diagnosis of an intracranial germinoma usually is based on biopsy, because the features on neuroimaging are similar to other tumors.
Cytology of the CSF often is studied to detect metastasis into the spine. This is important for staging and radiotherapy planning.
Intracranial germinomas have a reported 90% survival to five years after diagnosis.[1] Near total resection does not seem to influence the cure rate, so gross total resection is not necessary and can increase the risk of complications from surgery. The best results have been reported from craniospinal radiation with local tumor boost of greater than 4,000 cGy.
Treatment and prognosis
Germinomas, like several other types of germ cell tumor, are sensitive to both chemotherapy[1] and radiotherapy. For this reason, with treatment patients' chances of long term survival, even cure, is excellent.
Although chemotherapy can shrink germinomas, it is not generally recommended alone unless there are contraindications to radiation possibly based on a study in the early 1990s where carboplatinum, etoposide and bleomycin were given to 45 germinoma patients. About half the patients relapsed. Most of these relapsed patients were recovered with radiation or additional chemotherapy.[1]
See also
References
External links
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
